AdventHealth

 

SABCS 2022 Conference Coverage
W

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Year Results From the monarchE Study

By SABCS 2022 Conference Coverage FEATURING Wassim Mchayleh
By SABCS 2022 Conference Coverage FEATURING Wassim Mchayleh
302 views
February 7, 2023
0 Comments
Login to view comments. Click here to Login
Oncology
20:07
2024 ESMO Annual Meeting Insights Hub

ESMO 2024 Summary: Key Trial Results in Advanced Bladder Cancer Trea…

Feat. G. Sonpavde
22:27
2024 ASCO® Annual Meeting Insights Hub

Developmental Therapeutics Highlights From ASCO® 2024

Feat. G. Sonpavde
20:41
2024 ASCO® Annual Meeting Insights Hub

Bladder Cancer Highlights From ASCO® 2024

Feat. G. Sonpavde
17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
13:54
AdventHealth

FDA Approval of Gemcitabine-Cisplatin + Nivo as 1L Therapy for Advan…

Feat. G. Sonpavde
14:00
Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Summary: "Key Highlights in Bladder/Urothelial Ca…

Feat. G. Sonpavde
31:30
Insights from 2023 ESMO Annual Meeting

ESMO23 Highlights in Urothelial Carcinoma

Feat. G. Sonpavde, B. McGregor
22:19
Insights from 2023 ESMO Annual Meeting

Bladder Cancer Highlights From ESMO 2023: Comparing and Contrasting …

Feat. G. Sonpavde
13:54
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "Key Bladder Cancer/Urothelial Carcinoma Up…

Feat. G. Sonpavde
09:12
AdventHealth

Update on the FDA Accelerated Approval of Enfortumab Vedotin + Pembr…

Feat. G. Sonpavde
04:35
ESMO 2022 Conference Coverage

ESMO 2022 on the 4-Factor Model to Predict Response and Survival Ben…

Feat. G. Sonpavde
12:10
ESMO 2022 Conference Coverage

ESMO 2022: Key Bladder Cancer/Urothelial Carcinoma Presentations

Feat. G. Sonpavde
09:01
SABCS 2022 Conference Coverage

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Ye…

Feat. W. Mchayleh